Prit Lakhani

Prit Lakhani

Auto-generated profile, based on publicly available information

Prit Lakhani

Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, Oxford, Mississippi

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SBSwati Biswas
Swati Biswas
PKPreeti Kumari
Preeti Kumari
PLPrit Manish Lakhani
Prit Manish Lakhani
BGBalaram Ghosh
Balaram Ghosh

10 October 2017 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
HDHuy Dao
Huy Dao
PLPrit Lakhani
Prit Lakhani
APAnitha Police
Anitha Police
VKVenkataraman Kallakunta
Venkataraman Kallakunta
SASankar Srinivas Ajjarapu
Sankar Srinivas Ajjarapu
SMS. Narasimha Murthy
S. Narasimha Murthy

30 January 2019 in Journal of Ocular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PLPrit Lakhani
Prit Lakhani
APAkash Patil
Akash Patil
SMSoumyajit Majumdar
Soumyajit Majumdar
Polyenes and azoles constitute 2 major drug classes in the antifungal armamentarium used to treat fungal infections of the eye such as fungal keratitis, endophthalmitis, conjunctivitis, and blepharitis. These classes of drugs have come to occupy an important niche in ophthalmic antifungal therapy due to their broad spectrum of activity against a variety of filamentous and yeast-like fungi. Natamycin suspension (Natacyn ® ), a polyene antifungal drug, is currently the only US FDA-approved formulation for treating ophthalmic fungal infections, whereas the other polyene and azole antifungals such as amphotericin B, fluconazole, itraconazole, ketoconazole, miconazole, voriconazole, and posaconazole are routinely used off-label in the clinical setting. Despite potent antifungal activity, the clinical utility of these agents in ophthalmic infections has been challenged by their physicochemical properties, the unique ocular anatomy and physiology, selective antifungal activity, ocular and systemic toxicity, emergence of resistance and cross-resistance, and absence of reliable techniques for developing a robust in vitro-in vivo correlation. This review discusses the aforementioned challenges and the common approaches undertaken to circumnavigate the difficulties associated with the polyene- and azole-based pharmacotherapy of ophthalmic fungal infections.

1 October 2018 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
PLPrit Lakhani
Prit Lakhani
APAkash Patil
Akash Patil
PTPranjal Taskar
Pranjal Taskar
EAEman A. Ashour
Eman A. Ashour
SMSoumyajit Majumdar
Soumyajit Majumdar

12 January 2018 in Therapeutic Delivery
Verified
Journal Article
Closed access
PLPrit Lakhani
Prit Lakhani
APAkash Patil
Akash Patil
SMSoumyajit Majumdar
Soumyajit Majumdar
Over the past decade, there has been a rise in the number of clinical cases of moderate to severe anterior segment ocular diseases. Conventional topical ophthalmic formulations have several limitations – to address which, novel drug-delivery systems are needed. Additionally, formidable physiological barriers limit ocular bioavailability through the topical route of application. During the last decade, various nano-scaled ocular drug-delivery strategies have been reported. Some of these exploratory, topical, noninvasive approaches have shown promise in improving penetration into the anterior segment tissues of the eye. In this article, we review the available literature with respect to the safety, efficiency and effectiveness of these nano systems.

1 August 2018 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
APAkash Patil
Akash Patil
PLPrit Lakhani
Prit Lakhani
PTPranjal Taskar
Pranjal Taskar
KWKai-Wei Wu
Kai-Wei Wu
CSCorinne Sweeney
Corinne Sweeney
SMSoumyajit Majumdar
Soumyajit Majumdar